Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Practical Insights on Key Data From ESMO 2020 Informing Precision Medicine in NSCLC

In this pocast episode, listen to Helena A. Yu, MD, a medical oncologist, and Maria E. Arcila, MD, a molecular pathologist, discuss new data on actionable mutations and targeted therapies in NSCLC from ESMO 2020, including emerging therapeutic strategies targeting EGFR or KRAS G12C driver mutations.
person default
Maria E. Arcila, MD
Helena A. Yu, MD
Released: December 21, 2020

In this episode, Helena A. Yu, MD, and Maria E. Arcila, MD, provide medical oncology and pathology perspectives, respectively, on new data from ESMO 2020 informing precision medicine in NSCLC, with topics including:

  • Updated efficacy data from the phase III ADAURA study of adjuvant osimertinib for resected EGFR-mutated NSCLC with a focus on CNS disease recurrence
  • Biomarker testing in early-stage lung cancer 
  • New data for sotorasib, a small molecule inhibitor of KRAS G12C, in heavily pretreated NSCLC
  • Interim results from the phase I portion of the CHRYSALIS trial evaluating amivantamab, a bispecific antibody that targets EGFR and MET, in combination with lazertinib, a third-generation EGFR TKI, for the treatment of EGFR-mutated NSCLC
  • Phase I data on the HER3-directed antibody–drug conjugate patritumab deruxtecan for NSCLC with progression on an EGFR TKI

Presenters:

Helena A. Yu, MD
Assistant Attending
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Maria E. Arcila, MD
Pathologist
Director, Diagnostic Molecular Pathology Laboratory
Memorial Sloan Kettering Cancer Center
New York, New York

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Lilly

For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Related Content

Update of ATEZO-BRAIN trial evaluating atezolizumab plus chemotherapy in patients with advanced nonsquamous NSCLC with untreated brain metastases, presented at ASCO 2022 and reported by Clinical Care Options (CCO)

Released: June 16, 2022

Phase I CHRYSALIS-2 updates: amivantamab + lazertinib in EGFRm NSCLC after progression with osimertinib and chemotherapy, presented at ASCO 2022 and reported by Clinical Care Options (CCO)

Released: June 14, 2022

Adagrasib shows early encouraging activity in patients with KRAS G12C-mutant NSCLC and active, untreated CNS metastases, from Clinical Care Options (CCO) coverage of ASCO 2022

Released: June 13, 2022

Phase II NADIM II trial evaluating neoadjuvant nivolumab plus chemotherapy for resectable stage IIIA/B NSCLC, presented at ASCO 2022 and reported by Clinical Care Options (CCO)

Released: June 10, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings